Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137551 · ClinicalTrials.gov registry record · NA
ABM for ACO Beneficiaries
A NA study, sponsored by American Pharmacists Association Foundation.
- Completed
- Registry status
- NA
- Development phase
- 595
- Enrollment target
NCT02137551: Completed NA study, sponsored by American Pharmacists Association Foundation.
NCT02137551 is a NA study that has completed, run by American Pharmacists Association Foundation. The registered enrollment target is 595 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02137551, a NA study, has completed, sponsored by American Pharmacists Association Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 595 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate how engaging ACO beneficiaries in the appointment based model for one year impacts medication adherence and healthcare costs compared to usual care.
Primary Outcome
Total medical costs will be collected at baseline for the year prior to enrollment and at the end of the one-year study period for the intervention year.
Interventions
- OTHER ABM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-02 |
| Phase | NA |
What the finished NCT02137551 record still lists
NCT02137551 is an interventional study that assigns participants to a tested intervention. The registered 595 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which ABM is the first listed.
NCT02137551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02137551 about?
NCT02137551 is a clinical study titled "ABM for ACO Beneficiaries". The primary objective of the study is to evaluate how engaging ACO beneficiaries in the appointment based model for one year impacts medication adherence and healthcare costs compared to usual care.
What is the current status of trial NCT02137551?
This trial is currently completed. It is a NA study. The enrollment target is 595 participants. The study started on 2014-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02137551?
The interventions under investigation include: ABM (OTHER).
Who is sponsoring clinical trial NCT02137551?
This trial is sponsored by American Pharmacists Association Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02137551's enrollment target sits among peer trials
595 174th of 2000 higher than 1,827 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05723198 · 595 participants · Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia